Correction of Anemia with Continuous Erythropoietin Receptor Activator in Korean Patients on Long-Term Hemodialysis.
10.3346/jkms.2014.29.1.76
- Author:
Jieun OH
1
;
Kwon Wook JOO
;
Ho Jun CHIN
;
Dong Wan CHAE
;
Sung Gyun KIM
;
Soo Jin KIM
;
Wookyung CHUNG
;
Sejoong KIM
;
Wooseong HUH
;
Ha Young OH
;
Bum Soon CHOI
;
Chul Woo YANG
;
Suhnggwon KIM
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Hallym Kidney Research Institute, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial, Phase III ; Multicenter Study ; Research Support, Non-U.S. Gov't ; Randomized Controlled Trial
- Keywords:
Anemia Correction;
Continuous Erythropoietin Receptor Activator;
Kidney Failure, Chronic;
Renal Dialysis
- MeSH:
Anemia/*drug therapy;
Erythropoietin/*therapeutic use;
Female;
Hemoglobins/analysis;
Humans;
Male;
Middle Aged;
Polyethylene Glycols/*therapeutic use;
Quality of Life;
Recombinant Proteins/therapeutic use;
Renal Dialysis;
Renal Insufficiency, Chronic/*drug therapy;
Republic of Korea
- From:Journal of Korean Medical Science
2014;29(1):76-83
- CountryRepublic of Korea
- Language:English
-
Abstract:
Continuous erythropoietin receptor activator (CERA) is an erythropoietin with a long-half life. This study investigated the efficacy of CERA for correcting anemia in Korean patients on dialysis. Patients (> or =18 yr) who were not receiving any ESAs for more than 8 weeks were randomly assigned to either intravenous CERA once every 2 weeks (n=39) or epoetin beta thrice-weekly (n=41) during a 24-week correction phase. Hemoglobin (Hb) response was defined as increase of Hb by at least 1 g/dL and Hb> or =11 g/dL without red blood cell (RBC) transfusion. Median dialysis duration was 1.7 (0.3-20.8) and 1.6 (0.4-13.8) yr in CERA and epoetin beta group, respectively. Hemoglobin response rate of CERA was 79.5% (95% confidence interval [CI], 63.5-90.7). As the lower limit of 95% CI was higher than pre-specified 60% response rate, it can be concluded that CERA corrected anemia (P<0.05). Hb response rate of epoetin beta was 87.8% (95% CI, 73.8-95.9) (P=0.37). Median time to response was 12 weeks in CERA and 10.3 weeks in epoetin beta (P=0.03). It is suggested that once every 2 weeks administration of CERA is effective for correcting anemia in Korean patients on long-term hemodialysis with longer time-to-response than thrice weekly epoetin beta. (ClinicalTrials.gov registry No. NCT00546481)
